R. Heine

Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study

Laura A. Hatfield, V. Novack, L. Lix, 2022, BMJ.

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future

M. Kersten, U. Jaeger, H. Einsele, 2021, HemaSphere.

Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma.

F. Thielen, Renaud Heine, C. D. Groot, 2022, Cytotherapy.

Differences in Treatment Patterns and Outcomes of Acute Myocardial Infarction for Low- and High-Income Patients in 6 Countries.

Laura A. Hatfield, L. Lix, P. Cram, 2023, JAMA.

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe

J. Verweij, C. U. Uyl‐de Groot, M. Krol, 2020, Cancers.

Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach.

P. Wetzelaer, B. Pongiglione, H. Blommestein, 2022, Health economics.

Sex-Based Disparities in Acute Myocardial Infarction Treatment Patterns and Outcomes in Older Adults Hospitalized Across 6 High-Income Countries: An Analysis From the International Health Systems Research Collaborative

L. Pasea, S. Al-Azazi, P. Bakx, 2024, Circulation. Cardiovascular quality and outcomes.

Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab

R. Heine, R. Mathijssen, C. A. Uyl-de Groot, 2024, PloS one.